×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Transgenic Animals Market Size

ID: MRFR/LS/4018-HCR
110 Pages
Kinjoll Dey
February 2026

Transgenic Animals Market Research Report by Products (Gene Gun, Microinjection), Techniques (DNA Microinjection), Consumables (Probes), Application (Monoclonal Abs), Transgenic Animals (Mice) End User (Biotech Industries) - Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Transgenic Animals Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Transgenic Animals Size

Transgenic Animals Market Growth Projections and Opportunities

The TRANSGENIC ANIMALS MARKET is substantially encouraged by the demand for transgenic animals in biomedical research. Increased use of genetically changed animals in analyzing illnesses, drug development, and know-how biological tactics drives the market's growth, as researchers are looking for more sophisticated trends for their experiments. Advances in genetic engineering technologies play a pivotal function in shaping the TRANSGENIC ANIMALS MARKET. Continuous enhancements in the precision and efficiency of gene-modifying gear make contributions to the improvement of a wider range of transgenic animals with specific genetic adjustments, expanding the market's potential packages. Collaborations between the pharmaceutical and biotechnology industries and studies establishments force innovation inside the TRANSGENIC ANIMALS MARKET. Partnerships facilitate the improvement of custom-designed animal models for drug testing and research functions, fostering market growth and increasing the capabilities of transgenic animal technologies. The market is evolving with the exploration of transgenic animal applications in agriculture. Genetic changes in animals for advanced farm animals trends, disorder resistance, and improved agricultural productiveness contribute to the market's growth past biomedical research, creating new possibilities. The value-effectiveness of genetic amendment strategies influences the TRANSGENIC ANIMALS MARKET. Advances in an era that lessens the cost and time required for genetic adjustments make transgenic animals more reachable to researchers and industries, fostering increased adoption and market growth. Public belief and the reputation of transgenic animals affect the market's development. Ethical considerations, environmental worries, and societal attitudes in the direction of genetically modified organisms play a role in shaping the market panorama. Public training and recognition tasks are crucial for addressing those factors. Concerns associated with the welfare of transgenic animals are vital market elements. Ethical treatment and responsible care of genetically modified animals are vital for gaining public trust and regulatory approval, influencing market dynamics, and shaping the industry's moral practices. The stage of technological competitiveness amongst market players is a used element within the TRANSGENIC ANIMALS MARKET. Companies making an investment in current technology and staying at the forefront of genetic engineering improvements have an aggressive side, influencing market trends and innovations.

Transgenic Animals Market Size Graph
Author
Kinjoll Dey
Senior Research Analyst

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Get In Touch

Leave a Comment

FAQs

What is the current valuation of the Transgenic Animals Market?

<p>The Transgenic Animals Market was valued at 3.56 USD Billion in 2024.</p>

What is the projected market size for the Transgenic Animals Market by 2035?

<p>The market is projected to reach 10.66 USD Billion by 2035.</p>

What is the expected CAGR for the Transgenic Animals Market during the forecast period?

<p>The expected CAGR for the market from 2025 to 2035 is 10.48%.</p>

Which companies are considered key players in the Transgenic Animals Market?

<p>Key players include Heska Corporation, Genus plc, and Novartis AG, among others.</p>

What are the primary applications of transgenic animals in the market?

<p>Applications include recombinant human proteins, monoclonal antibodies, and xenotransplantation.</p>

What techniques are commonly used in the production of transgenic animals?

Common techniques include retro-virus-mediated transfer of gene and microinjection of DNA.

Which model organisms dominate the Transgenic Animals Market?

Mice and rats are the dominant model organisms, with projected valuations of 4.5 and 2.4 USD Billion, respectively.

What are the main end-user segments in the Transgenic Animals Market?

End-users include the biotechnological industry, research organizations, and academic institutes.

How does the market for transgenic animals compare across different techniques?

The microinjection technique is projected to grow from 1.6 to 4.84 USD Billion during the forecast period.

What is the significance of the biotechnological industry in the Transgenic Animals Market?

The biotechnological industry is expected to grow from 1.78 to 5.25 USD Billion, indicating its crucial role in market expansion.

Market Summary

As per Market Research Future analysis, the Transgenic Animals Market Size was estimated at 3.56 USD Billion in 2024. The Transgenic Animals industry is projected to grow from 3.933 USD Billion in 2025 to 10.66 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 10.48% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Transgenic Animals Market is poised for substantial growth driven by technological advancements and increasing applications in various sectors.

  • Advancements in genetic engineering are significantly shaping the transgenic animals market, particularly in North America, which remains the largest market. The Asia-Pacific region is emerging as the fastest-growing area, reflecting a rising interest in sustainable agricultural practices. Microinjections continue to dominate as the largest segment, while electroporators are gaining traction as the fastest-growing method for gene transfer. Rising demand for biopharmaceuticals and regulatory support for biotechnology are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 3.56 (USD Billion)
2035 Market Size 10.66 (USD Billion)
CAGR (2025 - 2035) 10.48%
Largest Regional Market Share in 2024 America

Major Players

Heska Corporation (US), Genus plc (GB), Auburn University (US), Transgenic Animal Production (US), Recombinetics, Inc. (US), University of California (US), Horizon Discovery Group plc (GB), Kymab Limited (GB), Novartis AG (CH)

Market Trends

The Transgenic Animals Market is currently experiencing a notable evolution, driven by advancements in genetic engineering and biotechnology. This sector encompasses a variety of applications, including agriculture, pharmaceuticals, and research. The increasing demand for genetically modified organisms, particularly in livestock, suggests a shift towards enhanced productivity and disease resistance. Furthermore, the growing interest in personalized medicine and the development of transgenic models for human diseases indicate a promising future for this market. As regulatory frameworks evolve, the potential for innovation within the Transgenic Animals Market appears to expand, fostering collaboration between academia and industry. In addition, ethical considerations surrounding the use of transgenic animals are becoming more prominent. Stakeholders are increasingly aware of the need for responsible practices and transparency in genetic modifications. This awareness may lead to the establishment of stricter guidelines and standards, which could influence market dynamics. Overall, the Transgenic Animals Market seems poised for growth, with ongoing research and development efforts likely to drive new applications and technologies in the coming years.

Advancements in Genetic Engineering

Recent innovations in genetic modification techniques are transforming the Transgenic Animals Market. Techniques such as CRISPR and other genome editing tools are enabling more precise alterations, which may enhance the efficiency and effectiveness of transgenic applications. This trend indicates a shift towards more targeted approaches in creating genetically modified organisms.

Increased Focus on Animal Welfare

There is a growing emphasis on ethical considerations and animal welfare within the Transgenic Animals Market. Stakeholders are increasingly advocating for responsible practices in genetic modifications, which may lead to the development of guidelines that prioritize the well-being of transgenic animals. This trend reflects a broader societal concern regarding the treatment of genetically altered organisms.

Expansion of Applications in Pharmaceuticals

The use of transgenic animals in pharmaceutical development is gaining traction. These animals are being utilized as models for human diseases, which could facilitate drug discovery and testing processes. This trend suggests a potential for significant advancements in medical research, as transgenic models may provide more accurate representations of human conditions.

Transgenic Animals Market Market Drivers

Regulatory Support for Biotechnology

Regulatory support for biotechnology is emerging as a key driver for the Transgenic Animals Market. Governments and regulatory bodies are increasingly recognizing the potential benefits of transgenic technologies in addressing global challenges such as food security and disease management. Initiatives aimed at streamlining the approval processes for genetically modified organisms are likely to encourage research and development in this field. For example, regulatory frameworks that facilitate the safe use of transgenic animals in agriculture and pharmaceuticals can enhance public acceptance and foster innovation. As regulatory environments become more favorable, the Transgenic Animals Market may experience accelerated growth, attracting investments and encouraging the development of new products and applications.

Rising Demand for Biopharmaceuticals

The increasing demand for biopharmaceuticals is a pivotal driver for the Transgenic Animals Market. As the healthcare sector evolves, there is a notable shift towards biologics, which are often produced using transgenic animals. These animals can be engineered to produce complex proteins and antibodies that are essential for therapeutic applications. The market for biopharmaceuticals is projected to reach approximately USD 500 billion by 2025, indicating a robust growth trajectory. This surge in demand is likely to propel the utilization of transgenic animals, as they offer a reliable and efficient means of producing high-quality biological products. Consequently, the Transgenic Animals Market is expected to witness significant expansion, driven by the need for innovative solutions in drug development and production.

Growing Interest in Sustainable Agriculture

The growing interest in sustainable agriculture is significantly influencing the Transgenic Animals Market. As consumers become more environmentally conscious, there is a rising demand for agricultural practices that minimize environmental impact. Transgenic animals can play a crucial role in this transition by providing enhanced traits such as improved feed efficiency and reduced greenhouse gas emissions. For instance, transgenic livestock can be engineered to utilize feed more effectively, thereby reducing waste and resource consumption. This shift towards sustainability is expected to drive the adoption of transgenic technologies in agriculture, leading to a more resilient food system. Consequently, the Transgenic Animals Market is poised for growth as stakeholders seek innovative solutions to meet the challenges of food security and environmental sustainability.

Increased Investment in Research and Development

Increased investment in research and development is a significant driver for the Transgenic Animals Market. As the potential applications of transgenic animals expand, both public and private sectors are allocating substantial resources to explore innovative solutions. This investment is crucial for advancing genetic engineering techniques and developing new transgenic species that can meet specific market needs. For instance, funding for research projects focused on disease-resistant animals or those with enhanced nutritional profiles is on the rise. Such initiatives not only contribute to scientific knowledge but also pave the way for commercial applications that can benefit various industries. The influx of capital into the Transgenic Animals Market is likely to stimulate growth and foster a dynamic environment for innovation.

Technological Advancements in Genetic Engineering

Technological advancements in genetic engineering are transforming the landscape of the Transgenic Animals Market. Innovations such as CRISPR-Cas9 and other gene-editing technologies have enhanced the precision and efficiency of creating transgenic animals. These advancements allow for the development of animals with specific traits, which can be utilized in various sectors, including agriculture and pharmaceuticals. The ability to produce animals that are disease-resistant or have improved growth rates can lead to increased productivity and sustainability in livestock farming. As these technologies continue to evolve, they are likely to drive further investment and research in the Transgenic Animals Market, fostering a more competitive environment and expanding the range of applications for transgenic animals.

Market Segment Insights

By Type: Microinjections (Largest) vs. Electroporator (Fastest-Growing)

<p>In the Transgenic Animals Market, microinjections hold the largest market share among the various methods utilized for genetic modification. This technique is widely adopted due to its reliability and precision in delivering foreign DNA into the oocyte or zygote, making it essential in producing transgenic animals. Meanwhile, the electroporator has emerged as a promising method, capturing attention for its increasing adoption in laboratories, thanks to its non-invasive approach and efficiency in gene transfer, positioning it as a key player in this competitive landscape.</p>

<p>Technology: Microinjections (Dominant) vs. Electroporator (Emerging)</p>

<p>Microinjections are regarded as the dominant technology in the transgenic animals market due to their established efficacy and widespread acceptance. This method allows for targeted delivery of genetic material, enabling precise modifications, which are crucial for research and agricultural applications. On the other hand, the electroporator is quickly emerging as a preferred alternative, particularly in specialized research settings. This method uses electrical pulses to create temporary pores in cell membranes, facilitating gene uptake. With its potential to enhance transformation efficiency and adaptability to various cell types, the electroporator is expected to gain traction and reshape the market dynamics in the coming years.</p>

By Techniques: Microinjection of DNA (Largest) vs. Retro-virus-mediated Transfer of Gene (Fastest-Growing)

<p>The transgenic animals market reveals a diverse distribution of techniques used for gene transfer, with microinjection of DNA holding the largest share. This traditional methodology is widely favored for the creation of genetically modified animals due to its direct approach and proven efficiency. On the other hand, retro-virus-mediated transfer of gene is rapidly gaining traction, appealing to researchers seeking innovative methods for gene integration. As scientists explore various techniques, embryonic stem cell-mediated transfer remains a significant consideration, although it is currently overshadowed by the aforementioned methods in terms of market presence. Growth trends point toward a surging interest in retro-virus-mediated methods as advancements in viral vector engineering enhance their safety and efficacy. The ongoing research in gene therapy and regenerative medicine bolsters the demand for transgenic animals, ultimately stimulating the use of these techniques. Continuous innovation and an increasing focus on precision breeding practices are crucial factors driving the popularity of these technologies in the market. As applications of transgenic animals expand, the techniques employed will likely evolve to meet new research and clinical demands.</p>

<p>Technique: Microinjection of DNA (Dominant) vs. Retro-virus-mediated Transfer of Gene (Emerging)</p>

<p>Microinjection of DNA stands as the dominant technique within the transgenic animals market, renowned for its straightforward methodology and established success in generating genetically modified organisms. It involves the direct insertion of foreign DNA into the pronucleus of a fertilized oocyte, which has been a staple in many pioneering studies and applications. Conversely, the retro-virus-mediated transfer of gene presents an emerging alternative that is rapidly gaining ground due to its higher efficiency in gene delivery and potential for enhanced integration stability. This technique uses modified viruses to introduce genetic material into host cells, thus offering promising avenues for future biotechnological applications. As the field progresses, both techniques are likely to complement each other, catering to diverse research needs in transgenics.</p>

By Applications: Recombinant Human Proteins (Largest) vs. Monoclonal Antibodies (Fastest-Growing)

<p>In the Transgenic Animals Market, recombinant human proteins dominate the applications segment, accounting for a substantial share driven by their widespread use in therapeutic development and research. Monoclonal antibodies are also significant players, characterized by a rapidly increasing share fueled by their essential role in modern immunotherapy and treatment processes, particularly in cancer and autoimmune disorders.</p>

<p>Recombinant Human Proteins (Dominant) vs. Monoclonal Antibodies (Emerging)</p>

<p>Recombinant human proteins are largely seen as the dominant force within the transgenic applications, as they leverage genetic engineering techniques for the production of essential therapeutic proteins, which are crucial for treating various diseases and disorders. Their established role in pharmaceutical development provides steady demand and supports extensive research. Conversely, monoclonal antibodies, while already an established segment, are rapidly emerging as a focal point due to advancements in biotechnology, leading to innovative therapies and personalized medicine approaches. The increasing prevalence of chronic diseases is propelling growth, establishing monoclonal antibodies as an essential part of therapeutic strategies.</p>

By Model Organisms: Mouse (Largest) vs. Zebrafish (Fastest-Growing)

<p>Within the transgenic animals segment, mice occupy the largest market share due to their extensive use in genetic research and drug testing. This widespread application is supported by their well-mapped genome, coupled with the availability of numerous genetic modification techniques that enhance their utility in laboratories. Conversely, zebrafish are rapidly gaining traction, especially in developmental biology and drug discovery, attributed to their transparent embryos and rapid lifecycle that facilitate high-throughput screening. The growth of the transgenic animals segment is driven by increasing investments in genetic research and the advancement of genomic technologies. The emergence of zebrafish as a model organism reflects a shift towards more diverse models in research, catering to specific biological questions. Additionally, regulatory support and public acceptance of transgenic models continue to bolster market expansion, indicating a dynamic landscape ahead for model organisms in the transgenic animals market.</p>

<p>Mice (Dominant) vs. Zebrafish (Emerging)</p>

<p>Mice have established themselves as the dominant model organism in the transgenic animals market, mainly because of their physiological similarities to humans and extensive genetic knowledge base, providing researchers with a myriad of options for genetic manipulation. They play a critical role in studying diseases, testing therapeutics, and understanding complex biological pathways. On the other hand, zebrafish are becoming an emerging preference due to their unique advantages, such as external fertilization, optical clarity during early development, and rapid generation time. This allows researchers to conduct real-time observations of developmental processes and screen chemical compounds quickly. As the demand for efficient and innovative research methodologies grows, both mice and zebrafish will continue to shape the future of preclinical studies and genetic research.</p>

By End-Users: Biotechnological Industry (Largest) vs. Research Organizations (Fastest-Growing)

<p>The Transgenic Animals Market exhibits a significant market share distribution among its key end-users, primarily the biotechnological industry, research organizations, and academic institutes. The biotechnological industry holds the largest share due to its extensive application of transgenic animals for drug development, vaccine testing, and genetic research. On the other hand, research organizations are witnessing an increasing share as they expand their focus on genetic engineering and innovations in animal models, leading to a competitive landscape within this segment. Growth trends in the end-users segment highlight a shift towards collaboration between biotechnological firms and research organizations, accelerating advancements in transgenic technologies. The increasing demand for customized animal models for research and the rising number of genetic studies fuel the expansion of both segments. Furthermore, academic institutes are integrating transgenic models into their curricula, driving interest and utilization among emerging researchers, thereby enhancing overall market dynamics.</p>

<p>Biotechnological Industry: Dominant vs. Research Organizations: Emerging</p>

<p>The biotechnological industry is a dominant player in the Transgenic Animals Market, leveraging transgenic technology to produce genetically modified animals for disease research, pharmaceutical development, and agricultural improvements. This sector benefits from established infrastructure, significant investments in R&D, and a strong regulatory framework that supports innovation. In contrast, research organizations are emerging as a vital segment in this market. Their increasing focus on developing advanced animal models for specific studies, combined with flexible funding from governmental and private sectors, allows them to adapt quickly to new scientific challenges. The collaboration between these two segments fosters a synergistic environment, enhancing the overall efficiency of research and application in transgenic animal technology.</p>

Get more detailed insights about Transgenic Animals Market Research Report – Forecast till 2035

Regional Insights

North America : Innovation and Research Hub

North America dominates the transgenic animals market, accounting for approximately 45% of the global share. The region benefits from robust research institutions, significant funding for biotechnology, and favorable regulatory frameworks that encourage innovation. The increasing demand for genetically modified animals for agricultural and pharmaceutical applications further drives market growth. Regulatory bodies like the USDA and FDA play crucial roles in shaping the landscape, ensuring safety and efficacy in transgenic animal production. The United States is the largest market, followed by Canada, which is emerging as a significant player. Key companies such as Heska Corporation, Genus plc, and various universities are at the forefront of research and development. The competitive landscape is characterized by collaborations between academia and industry, fostering advancements in genetic engineering and transgenic technologies. This synergy enhances the region's position as a leader in the transgenic animals market.

Europe : Regulatory Framework and Innovation

Europe is a significant player in the transgenic animals market, holding approximately 30% of the global share. The region's growth is driven by stringent regulations that ensure the safety and ethical considerations of transgenic animals. The European Food Safety Authority (EFSA) plays a pivotal role in assessing the risks associated with genetically modified organisms, which influences market dynamics. The increasing focus on sustainable agriculture and animal welfare further propels demand for transgenic solutions. Leading countries in Europe include the United Kingdom, Germany, and Switzerland, where key players like Genus plc and Novartis AG are actively involved in research and development. The competitive landscape is marked by collaborations between biotech firms and research institutions, enhancing innovation in transgenic technologies. The presence of strong regulatory bodies ensures that the market operates within a framework that prioritizes safety and ethical standards, fostering consumer trust and acceptance.

Asia-Pacific : Emerging Market with Potential

Asia-Pacific is an emerging powerhouse in the transgenic animals market, accounting for approximately 20% of the global share. The region's growth is fueled by increasing investments in biotechnology, rising demand for food security, and advancements in genetic engineering technologies. Countries like China and India are leading the charge, with supportive government policies aimed at enhancing agricultural productivity through transgenic solutions. The regulatory environment is evolving, with efforts to establish frameworks that balance innovation and safety. China is the largest market in the region, followed by India, where significant research initiatives are underway. The competitive landscape features a mix of local and international players, with collaborations between universities and biotech firms driving innovation. The presence of key players like Recombinetics, Inc. and various research institutions enhances the region's capabilities in transgenic animal production, positioning it for future growth in the global market.

Middle East and Africa : Resource-Rich with Growth Potential

The Middle East and Africa region is gradually emerging in the transgenic animals market, holding about 5% of the global share. The growth is primarily driven by increasing agricultural challenges, food security concerns, and the need for innovative solutions to enhance livestock productivity. Countries like South Africa and Egypt are beginning to explore transgenic technologies, supported by government initiatives aimed at improving agricultural practices. The regulatory landscape is still developing, with efforts to establish guidelines for the safe use of transgenic animals. South Africa is the leading market in the region, with a growing interest in biotechnology and transgenic research. The competitive landscape is characterized by collaborations between local universities and international biotech firms, fostering knowledge transfer and innovation. As awareness of the benefits of transgenic animals increases, the region is poised for growth, with potential for significant advancements in agricultural productivity and food security.

Key Players and Competitive Insights

The Transgenic Animals Market is currently characterized by a dynamic competitive landscape, driven by advancements in genetic engineering and increasing demand for genetically modified organisms in agriculture and pharmaceuticals. Key players such as Heska Corporation (US), Genus plc (GB), and Recombinetics, Inc. (US) are strategically positioned to leverage innovation and partnerships to enhance their market presence. These companies focus on developing transgenic solutions that address specific agricultural challenges and improve livestock health, thereby shaping a competitive environment that emphasizes technological advancement and regulatory compliance.

In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears moderately fragmented, with several players vying for dominance. However, the collective influence of major companies like Novartis AG (CH) and Horizon Discovery Group plc (GB) suggests a trend towards consolidation, as these firms seek to expand their portfolios through strategic acquisitions and collaborations.

In August 2025, Genus plc (GB) announced a partnership with a leading agricultural technology firm to develop transgenic pigs resistant to specific diseases. This collaboration is expected to enhance Genus's product offerings and strengthen its position in the livestock sector. The strategic importance of this partnership lies in its potential to address pressing health issues in swine production, thereby improving overall productivity and sustainability in the industry.

In September 2025, Recombinetics, Inc. (US) launched a new line of genetically modified cattle designed to thrive in extreme weather conditions. This initiative reflects a growing recognition of climate change impacts on agriculture. By focusing on resilience, Recombinetics aims to provide farmers with livestock that can adapt to changing environmental conditions, thus ensuring food security and sustainability.

Furthermore, in July 2025, Heska Corporation (US) expanded its research capabilities by acquiring a biotechnology firm specializing in gene editing technologies. This acquisition is likely to enhance Heska's R&D efforts, enabling the company to innovate more rapidly and effectively in the transgenic space. The strategic move underscores the importance of technological advancement in maintaining competitive differentiation in a rapidly evolving market.

As of October 2025, current competitive trends indicate a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in transgenic animal development. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, as firms strive to meet the growing demands of a more environmentally conscious market.

Key Companies in the Transgenic Animals Market include

Industry Developments

    • In 2020, a famous manufacturer Merck Animal Health agreed with Automamaziono VX Inc., discovered a subcutaneous chick development technology. This technology will be used for combining Merck Animal Health’s Innovax vaccines which are used for protection against infectious diseases.
    • In 2019, Boehringer Ingelheim put forward the largest biotechnology for the discovery of veterinary vaccines in France. Here demand increased along with the rise in growth in poultry consumption.
    • In April 2020, Heska Corporation made a partnership with Scil Animal Care emerge and carried out new veterinary projects.
    • In June 2020, Chanelle Pharma Group discovered the Spot-On treatment which protects cats and dogs against some of the parasites.

 

Future Outlook

Transgenic Animals Market Future Outlook

The Transgenic Animals Market is projected to grow at a 10.48% CAGR from 2025 to 2035, driven by advancements in genetic engineering, increasing demand for biopharmaceuticals, and enhanced agricultural productivity.

New opportunities lie in:

  • <p>Development of genetically modified livestock for disease resistance Expansion of transgenic animal models for drug testing Investment in precision breeding technologies for enhanced traits</p>

By 2035, the Transgenic Animals Market is expected to achieve substantial growth and innovation.

Market Segmentation

Transgenic Animals Market Type Outlook

  • OCR gene gun
  • microinjections
  • electroporator

Transgenic Animals Market End-Users Outlook

  • biotechnological industry
  • research organizations
  • academic institutes

Transgenic Animals Market Techniques Outlook

  • retro-virus-mediated transfer of gene
  • embryonic stem cell-mediated transfer of gene
  • microinjection of DNA

Transgenic Animals Market Applications Outlook

  • recombinant human proteins
  • monoclonal antibodies
  • xenotransplantation

Report Scope

MARKET SIZE 2024 3.56(USD Billion)
MARKET SIZE 2025 3.933(USD Billion)
MARKET SIZE 2035 10.66(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 10.48% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Heska Corporation (US), Genus plc (GB), Auburn University (US), Transgenic Animal Production (US), Recombinetics, Inc. (US), University of California (US), Horizon Discovery Group plc (GB), Kymab Limited (GB), Novartis AG (CH)
Segments Covered Products
Key Market Opportunities Advancements in gene editing technologies enhance potential applications in the Transgenic Animals Market.
Key Market Dynamics Rising regulatory scrutiny and technological advancements drive innovation in the transgenic animals market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Transgenic Animals Market?

<p>The Transgenic Animals Market was valued at 3.56 USD Billion in 2024.</p>

What is the projected market size for the Transgenic Animals Market by 2035?

<p>The market is projected to reach 10.66 USD Billion by 2035.</p>

What is the expected CAGR for the Transgenic Animals Market during the forecast period?

<p>The expected CAGR for the market from 2025 to 2035 is 10.48%.</p>

Which companies are considered key players in the Transgenic Animals Market?

<p>Key players include Heska Corporation, Genus plc, and Novartis AG, among others.</p>

What are the primary applications of transgenic animals in the market?

<p>Applications include recombinant human proteins, monoclonal antibodies, and xenotransplantation.</p>

What techniques are commonly used in the production of transgenic animals?

Common techniques include retro-virus-mediated transfer of gene and microinjection of DNA.

Which model organisms dominate the Transgenic Animals Market?

Mice and rats are the dominant model organisms, with projected valuations of 4.5 and 2.4 USD Billion, respectively.

What are the main end-user segments in the Transgenic Animals Market?

End-users include the biotechnological industry, research organizations, and academic institutes.

How does the market for transgenic animals compare across different techniques?

The microinjection technique is projected to grow from 1.6 to 4.84 USD Billion during the forecast period.

What is the significance of the biotechnological industry in the Transgenic Animals Market?

The biotechnological industry is expected to grow from 1.78 to 5.25 USD Billion, indicating its crucial role in market expansion.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Type (USD Billion)
    2. | | 4.1.1 OCR gene gun
    3. | | 4.1.2 microinjections
    4. | | 4.1.3 electroporator
    5. | 4.2 Healthcare, BY Techniques (USD Billion)
    6. | | 4.2.1 retro-virus-mediated transfer of gene
    7. | | 4.2.2 embryonic stem cell-mediated transfer of gene
    8. | | 4.2.3 microinjection of DNA
    9. | 4.3 Healthcare, BY Applications (USD Billion)
    10. | | 4.3.1 recombinant human proteins
    11. | | 4.3.2 monoclonal antibodies
    12. | | 4.3.3 xenotransplantation
    13. | 4.4 Healthcare, BY Model Organisms (USD Billion)
    14. | 4.5 Healthcare, BY End-Users (USD Billion)
    15. | | 4.5.1 biotechnological industry
    16. | | 4.5.2 research organizations
    17. | | 4.5.3 academic institutes
    18. | 4.6 Healthcare, BY Region (USD Billion)
    19. | | 4.6.1 North America
    20. | | | 4.6.1.1 US
    21. | | | 4.6.1.2 Canada
    22. | | 4.6.2 Europe
    23. | | | 4.6.2.1 Germany
    24. | | | 4.6.2.2 UK
    25. | | | 4.6.2.3 France
    26. | | | 4.6.2.4 Russia
    27. | | | 4.6.2.5 Italy
    28. | | | 4.6.2.6 Spain
    29. | | | 4.6.2.7 Rest of Europe
    30. | | 4.6.3 APAC
    31. | | | 4.6.3.1 China
    32. | | | 4.6.3.2 India
    33. | | | 4.6.3.3 Japan
    34. | | | 4.6.3.4 South Korea
    35. | | | 4.6.3.5 Malaysia
    36. | | | 4.6.3.6 Thailand
    37. | | | 4.6.3.7 Indonesia
    38. | | | 4.6.3.8 Rest of APAC
    39. | | 4.6.4 South America
    40. | | | 4.6.4.1 Brazil
    41. | | | 4.6.4.2 Mexico
    42. | | | 4.6.4.3 Argentina
    43. | | | 4.6.4.4 Rest of South America
    44. | | 4.6.5 MEA
    45. | | | 4.6.5.1 GCC Countries
    46. | | | 4.6.5.2 South Africa
    47. | | | 4.6.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Heska Corporation (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Genus plc (GB)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Auburn University (US)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Transgenic Animal Production (US)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 Recombinetics, Inc. (US)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 University of California (US)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Horizon Discovery Group plc (GB)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Kymab Limited (GB)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 Novartis AG (CH)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY TYPE
    4. | 6.4 US MARKET ANALYSIS BY TECHNIQUES
    5. | 6.5 US MARKET ANALYSIS BY APPLICATIONS
    6. | 6.6 US MARKET ANALYSIS BY MODEL ORGANISMS
    7. | 6.7 US MARKET ANALYSIS BY END-USERS
    8. | 6.8 CANADA MARKET ANALYSIS BY TYPE
    9. | 6.9 CANADA MARKET ANALYSIS BY TECHNIQUES
    10. | 6.10 CANADA MARKET ANALYSIS BY APPLICATIONS
    11. | 6.11 CANADA MARKET ANALYSIS BY MODEL ORGANISMS
    12. | 6.12 CANADA MARKET ANALYSIS BY END-USERS
    13. | 6.13 EUROPE MARKET ANALYSIS
    14. | 6.14 GERMANY MARKET ANALYSIS BY TYPE
    15. | 6.15 GERMANY MARKET ANALYSIS BY TECHNIQUES
    16. | 6.16 GERMANY MARKET ANALYSIS BY APPLICATIONS
    17. | 6.17 GERMANY MARKET ANALYSIS BY MODEL ORGANISMS
    18. | 6.18 GERMANY MARKET ANALYSIS BY END-USERS
    19. | 6.19 UK MARKET ANALYSIS BY TYPE
    20. | 6.20 UK MARKET ANALYSIS BY TECHNIQUES
    21. | 6.21 UK MARKET ANALYSIS BY APPLICATIONS
    22. | 6.22 UK MARKET ANALYSIS BY MODEL ORGANISMS
    23. | 6.23 UK MARKET ANALYSIS BY END-USERS
    24. | 6.24 FRANCE MARKET ANALYSIS BY TYPE
    25. | 6.25 FRANCE MARKET ANALYSIS BY TECHNIQUES
    26. | 6.26 FRANCE MARKET ANALYSIS BY APPLICATIONS
    27. | 6.27 FRANCE MARKET ANALYSIS BY MODEL ORGANISMS
    28. | 6.28 FRANCE MARKET ANALYSIS BY END-USERS
    29. | 6.29 RUSSIA MARKET ANALYSIS BY TYPE
    30. | 6.30 RUSSIA MARKET ANALYSIS BY TECHNIQUES
    31. | 6.31 RUSSIA MARKET ANALYSIS BY APPLICATIONS
    32. | 6.32 RUSSIA MARKET ANALYSIS BY MODEL ORGANISMS
    33. | 6.33 RUSSIA MARKET ANALYSIS BY END-USERS
    34. | 6.34 ITALY MARKET ANALYSIS BY TYPE
    35. | 6.35 ITALY MARKET ANALYSIS BY TECHNIQUES
    36. | 6.36 ITALY MARKET ANALYSIS BY APPLICATIONS
    37. | 6.37 ITALY MARKET ANALYSIS BY MODEL ORGANISMS
    38. | 6.38 ITALY MARKET ANALYSIS BY END-USERS
    39. | 6.39 SPAIN MARKET ANALYSIS BY TYPE
    40. | 6.40 SPAIN MARKET ANALYSIS BY TECHNIQUES
    41. | 6.41 SPAIN MARKET ANALYSIS BY APPLICATIONS
    42. | 6.42 SPAIN MARKET ANALYSIS BY MODEL ORGANISMS
    43. | 6.43 SPAIN MARKET ANALYSIS BY END-USERS
    44. | 6.44 REST OF EUROPE MARKET ANALYSIS BY TYPE
    45. | 6.45 REST OF EUROPE MARKET ANALYSIS BY TECHNIQUES
    46. | 6.46 REST OF EUROPE MARKET ANALYSIS BY APPLICATIONS
    47. | 6.47 REST OF EUROPE MARKET ANALYSIS BY MODEL ORGANISMS
    48. | 6.48 REST OF EUROPE MARKET ANALYSIS BY END-USERS
    49. | 6.49 APAC MARKET ANALYSIS
    50. | 6.50 CHINA MARKET ANALYSIS BY TYPE
    51. | 6.51 CHINA MARKET ANALYSIS BY TECHNIQUES
    52. | 6.52 CHINA MARKET ANALYSIS BY APPLICATIONS
    53. | 6.53 CHINA MARKET ANALYSIS BY MODEL ORGANISMS
    54. | 6.54 CHINA MARKET ANALYSIS BY END-USERS
    55. | 6.55 INDIA MARKET ANALYSIS BY TYPE
    56. | 6.56 INDIA MARKET ANALYSIS BY TECHNIQUES
    57. | 6.57 INDIA MARKET ANALYSIS BY APPLICATIONS
    58. | 6.58 INDIA MARKET ANALYSIS BY MODEL ORGANISMS
    59. | 6.59 INDIA MARKET ANALYSIS BY END-USERS
    60. | 6.60 JAPAN MARKET ANALYSIS BY TYPE
    61. | 6.61 JAPAN MARKET ANALYSIS BY TECHNIQUES
    62. | 6.62 JAPAN MARKET ANALYSIS BY APPLICATIONS
    63. | 6.63 JAPAN MARKET ANALYSIS BY MODEL ORGANISMS
    64. | 6.64 JAPAN MARKET ANALYSIS BY END-USERS
    65. | 6.65 SOUTH KOREA MARKET ANALYSIS BY TYPE
    66. | 6.66 SOUTH KOREA MARKET ANALYSIS BY TECHNIQUES
    67. | 6.67 SOUTH KOREA MARKET ANALYSIS BY APPLICATIONS
    68. | 6.68 SOUTH KOREA MARKET ANALYSIS BY MODEL ORGANISMS
    69. | 6.69 SOUTH KOREA MARKET ANALYSIS BY END-USERS
    70. | 6.70 MALAYSIA MARKET ANALYSIS BY TYPE
    71. | 6.71 MALAYSIA MARKET ANALYSIS BY TECHNIQUES
    72. | 6.72 MALAYSIA MARKET ANALYSIS BY APPLICATIONS
    73. | 6.73 MALAYSIA MARKET ANALYSIS BY MODEL ORGANISMS
    74. | 6.74 MALAYSIA MARKET ANALYSIS BY END-USERS
    75. | 6.75 THAILAND MARKET ANALYSIS BY TYPE
    76. | 6.76 THAILAND MARKET ANALYSIS BY TECHNIQUES
    77. | 6.77 THAILAND MARKET ANALYSIS BY APPLICATIONS
    78. | 6.78 THAILAND MARKET ANALYSIS BY MODEL ORGANISMS
    79. | 6.79 THAILAND MARKET ANALYSIS BY END-USERS
    80. | 6.80 INDONESIA MARKET ANALYSIS BY TYPE
    81. | 6.81 INDONESIA MARKET ANALYSIS BY TECHNIQUES
    82. | 6.82 INDONESIA MARKET ANALYSIS BY APPLICATIONS
    83. | 6.83 INDONESIA MARKET ANALYSIS BY MODEL ORGANISMS
    84. | 6.84 INDONESIA MARKET ANALYSIS BY END-USERS
    85. | 6.85 REST OF APAC MARKET ANALYSIS BY TYPE
    86. | 6.86 REST OF APAC MARKET ANALYSIS BY TECHNIQUES
    87. | 6.87 REST OF APAC MARKET ANALYSIS BY APPLICATIONS
    88. | 6.88 REST OF APAC MARKET ANALYSIS BY MODEL ORGANISMS
    89. | 6.89 REST OF APAC MARKET ANALYSIS BY END-USERS
    90. | 6.90 SOUTH AMERICA MARKET ANALYSIS
    91. | 6.91 BRAZIL MARKET ANALYSIS BY TYPE
    92. | 6.92 BRAZIL MARKET ANALYSIS BY TECHNIQUES
    93. | 6.93 BRAZIL MARKET ANALYSIS BY APPLICATIONS
    94. | 6.94 BRAZIL MARKET ANALYSIS BY MODEL ORGANISMS
    95. | 6.95 BRAZIL MARKET ANALYSIS BY END-USERS
    96. | 6.96 MEXICO MARKET ANALYSIS BY TYPE
    97. | 6.97 MEXICO MARKET ANALYSIS BY TECHNIQUES
    98. | 6.98 MEXICO MARKET ANALYSIS BY APPLICATIONS
    99. | 6.99 MEXICO MARKET ANALYSIS BY MODEL ORGANISMS
    100. | 6.100 MEXICO MARKET ANALYSIS BY END-USERS
    101. | 6.101 ARGENTINA MARKET ANALYSIS BY TYPE
    102. | 6.102 ARGENTINA MARKET ANALYSIS BY TECHNIQUES
    103. | 6.103 ARGENTINA MARKET ANALYSIS BY APPLICATIONS
    104. | 6.104 ARGENTINA MARKET ANALYSIS BY MODEL ORGANISMS
    105. | 6.105 ARGENTINA MARKET ANALYSIS BY END-USERS
    106. | 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
    107. | 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNIQUES
    108. | 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATIONS
    109. | 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY MODEL ORGANISMS
    110. | 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USERS
    111. | 6.111 MEA MARKET ANALYSIS
    112. | 6.112 GCC COUNTRIES MARKET ANALYSIS BY TYPE
    113. | 6.113 GCC COUNTRIES MARKET ANALYSIS BY TECHNIQUES
    114. | 6.114 GCC COUNTRIES MARKET ANALYSIS BY APPLICATIONS
    115. | 6.115 GCC COUNTRIES MARKET ANALYSIS BY MODEL ORGANISMS
    116. | 6.116 GCC COUNTRIES MARKET ANALYSIS BY END-USERS
    117. | 6.117 SOUTH AFRICA MARKET ANALYSIS BY TYPE
    118. | 6.118 SOUTH AFRICA MARKET ANALYSIS BY TECHNIQUES
    119. | 6.119 SOUTH AFRICA MARKET ANALYSIS BY APPLICATIONS
    120. | 6.120 SOUTH AFRICA MARKET ANALYSIS BY MODEL ORGANISMS
    121. | 6.121 SOUTH AFRICA MARKET ANALYSIS BY END-USERS
    122. | 6.122 REST OF MEA MARKET ANALYSIS BY TYPE
    123. | 6.123 REST OF MEA MARKET ANALYSIS BY TECHNIQUES
    124. | 6.124 REST OF MEA MARKET ANALYSIS BY APPLICATIONS
    125. | 6.125 REST OF MEA MARKET ANALYSIS BY MODEL ORGANISMS
    126. | 6.126 REST OF MEA MARKET ANALYSIS BY END-USERS
    127. | 6.127 KEY BUYING CRITERIA OF HEALTHCARE
    128. | 6.128 RESEARCH PROCESS OF MRFR
    129. | 6.129 DRO ANALYSIS OF HEALTHCARE
    130. | 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    131. | 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    132. | 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
    133. | 6.133 HEALTHCARE, BY TYPE, 2024 (% SHARE)
    134. | 6.134 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
    135. | 6.135 HEALTHCARE, BY TECHNIQUES, 2024 (% SHARE)
    136. | 6.136 HEALTHCARE, BY TECHNIQUES, 2024 TO 2035 (USD Billion)
    137. | 6.137 HEALTHCARE, BY APPLICATIONS, 2024 (% SHARE)
    138. | 6.138 HEALTHCARE, BY APPLICATIONS, 2024 TO 2035 (USD Billion)
    139. | 6.139 HEALTHCARE, BY MODEL ORGANISMS, 2024 (% SHARE)
    140. | 6.140 HEALTHCARE, BY MODEL ORGANISMS, 2024 TO 2035 (USD Billion)
    141. | 6.141 HEALTHCARE, BY END-USERS, 2024 (% SHARE)
    142. | 6.142 HEALTHCARE, BY END-USERS, 2024 TO 2035 (USD Billion)
    143. | 6.143 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY TYPE, 2025-2035 (USD Billion)
    5. | | 7.2.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    6. | | 7.2.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    7. | | 7.2.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    8. | | 7.2.5 BY END-USERS, 2025-2035 (USD Billion)
    9. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    10. | | 7.3.1 BY TYPE, 2025-2035 (USD Billion)
    11. | | 7.3.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    12. | | 7.3.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    13. | | 7.3.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    14. | | 7.3.5 BY END-USERS, 2025-2035 (USD Billion)
    15. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    16. | | 7.4.1 BY TYPE, 2025-2035 (USD Billion)
    17. | | 7.4.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    18. | | 7.4.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    19. | | 7.4.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    20. | | 7.4.5 BY END-USERS, 2025-2035 (USD Billion)
    21. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    22. | | 7.5.1 BY TYPE, 2025-2035 (USD Billion)
    23. | | 7.5.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    24. | | 7.5.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    25. | | 7.5.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    26. | | 7.5.5 BY END-USERS, 2025-2035 (USD Billion)
    27. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    28. | | 7.6.1 BY TYPE, 2025-2035 (USD Billion)
    29. | | 7.6.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    30. | | 7.6.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    31. | | 7.6.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    32. | | 7.6.5 BY END-USERS, 2025-2035 (USD Billion)
    33. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    34. | | 7.7.1 BY TYPE, 2025-2035 (USD Billion)
    35. | | 7.7.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    36. | | 7.7.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    37. | | 7.7.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    38. | | 7.7.5 BY END-USERS, 2025-2035 (USD Billion)
    39. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    40. | | 7.8.1 BY TYPE, 2025-2035 (USD Billion)
    41. | | 7.8.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    42. | | 7.8.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    43. | | 7.8.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    44. | | 7.8.5 BY END-USERS, 2025-2035 (USD Billion)
    45. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    46. | | 7.9.1 BY TYPE, 2025-2035 (USD Billion)
    47. | | 7.9.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    48. | | 7.9.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    49. | | 7.9.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    50. | | 7.9.5 BY END-USERS, 2025-2035 (USD Billion)
    51. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    52. | | 7.10.1 BY TYPE, 2025-2035 (USD Billion)
    53. | | 7.10.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    54. | | 7.10.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    55. | | 7.10.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    56. | | 7.10.5 BY END-USERS, 2025-2035 (USD Billion)
    57. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    58. | | 7.11.1 BY TYPE, 2025-2035 (USD Billion)
    59. | | 7.11.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    60. | | 7.11.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    61. | | 7.11.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    62. | | 7.11.5 BY END-USERS, 2025-2035 (USD Billion)
    63. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.12.1 BY TYPE, 2025-2035 (USD Billion)
    65. | | 7.12.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    66. | | 7.12.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    67. | | 7.12.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    68. | | 7.12.5 BY END-USERS, 2025-2035 (USD Billion)
    69. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    70. | | 7.13.1 BY TYPE, 2025-2035 (USD Billion)
    71. | | 7.13.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    72. | | 7.13.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    73. | | 7.13.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    74. | | 7.13.5 BY END-USERS, 2025-2035 (USD Billion)
    75. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    76. | | 7.14.1 BY TYPE, 2025-2035 (USD Billion)
    77. | | 7.14.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    78. | | 7.14.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    79. | | 7.14.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    80. | | 7.14.5 BY END-USERS, 2025-2035 (USD Billion)
    81. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    82. | | 7.15.1 BY TYPE, 2025-2035 (USD Billion)
    83. | | 7.15.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    84. | | 7.15.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    85. | | 7.15.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    86. | | 7.15.5 BY END-USERS, 2025-2035 (USD Billion)
    87. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    88. | | 7.16.1 BY TYPE, 2025-2035 (USD Billion)
    89. | | 7.16.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    90. | | 7.16.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    91. | | 7.16.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    92. | | 7.16.5 BY END-USERS, 2025-2035 (USD Billion)
    93. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    94. | | 7.17.1 BY TYPE, 2025-2035 (USD Billion)
    95. | | 7.17.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    96. | | 7.17.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    97. | | 7.17.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    98. | | 7.17.5 BY END-USERS, 2025-2035 (USD Billion)
    99. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    100. | | 7.18.1 BY TYPE, 2025-2035 (USD Billion)
    101. | | 7.18.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    102. | | 7.18.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    103. | | 7.18.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    104. | | 7.18.5 BY END-USERS, 2025-2035 (USD Billion)
    105. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    106. | | 7.19.1 BY TYPE, 2025-2035 (USD Billion)
    107. | | 7.19.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    108. | | 7.19.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    109. | | 7.19.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    110. | | 7.19.5 BY END-USERS, 2025-2035 (USD Billion)
    111. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    112. | | 7.20.1 BY TYPE, 2025-2035 (USD Billion)
    113. | | 7.20.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    114. | | 7.20.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    115. | | 7.20.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    116. | | 7.20.5 BY END-USERS, 2025-2035 (USD Billion)
    117. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    118. | | 7.21.1 BY TYPE, 2025-2035 (USD Billion)
    119. | | 7.21.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    120. | | 7.21.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    121. | | 7.21.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    122. | | 7.21.5 BY END-USERS, 2025-2035 (USD Billion)
    123. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    124. | | 7.22.1 BY TYPE, 2025-2035 (USD Billion)
    125. | | 7.22.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    126. | | 7.22.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    127. | | 7.22.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    128. | | 7.22.5 BY END-USERS, 2025-2035 (USD Billion)
    129. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    130. | | 7.23.1 BY TYPE, 2025-2035 (USD Billion)
    131. | | 7.23.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    132. | | 7.23.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    133. | | 7.23.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    134. | | 7.23.5 BY END-USERS, 2025-2035 (USD Billion)
    135. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    136. | | 7.24.1 BY TYPE, 2025-2035 (USD Billion)
    137. | | 7.24.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    138. | | 7.24.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    139. | | 7.24.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    140. | | 7.24.5 BY END-USERS, 2025-2035 (USD Billion)
    141. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    142. | | 7.25.1 BY TYPE, 2025-2035 (USD Billion)
    143. | | 7.25.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    144. | | 7.25.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    145. | | 7.25.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    146. | | 7.25.5 BY END-USERS, 2025-2035 (USD Billion)
    147. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    148. | | 7.26.1 BY TYPE, 2025-2035 (USD Billion)
    149. | | 7.26.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    150. | | 7.26.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    151. | | 7.26.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    152. | | 7.26.5 BY END-USERS, 2025-2035 (USD Billion)
    153. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    154. | | 7.27.1 BY TYPE, 2025-2035 (USD Billion)
    155. | | 7.27.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    156. | | 7.27.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    157. | | 7.27.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    158. | | 7.27.5 BY END-USERS, 2025-2035 (USD Billion)
    159. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    160. | | 7.28.1 BY TYPE, 2025-2035 (USD Billion)
    161. | | 7.28.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    162. | | 7.28.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    163. | | 7.28.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    164. | | 7.28.5 BY END-USERS, 2025-2035 (USD Billion)
    165. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    166. | | 7.29.1 BY TYPE, 2025-2035 (USD Billion)
    167. | | 7.29.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    168. | | 7.29.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    169. | | 7.29.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    170. | | 7.29.5 BY END-USERS, 2025-2035 (USD Billion)
    171. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    172. | | 7.30.1 BY TYPE, 2025-2035 (USD Billion)
    173. | | 7.30.2 BY TECHNIQUES, 2025-2035 (USD Billion)
    174. | | 7.30.3 BY APPLICATIONS, 2025-2035 (USD Billion)
    175. | | 7.30.4 BY MODEL ORGANISMS, 2025-2035 (USD Billion)
    176. | | 7.30.5 BY END-USERS, 2025-2035 (USD Billion)
    177. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    178. | | 7.31.1
    179. | 7.32 ACQUISITION/PARTNERSHIP
    180. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

  • OCR gene gun
  • microinjections
  • electroporator

Healthcare By Techniques (USD Billion, 2025-2035)

  • retro-virus-mediated transfer of gene
  • embryonic stem cell-mediated transfer of gene
  • microinjection of DNA

Healthcare By Applications (USD Billion, 2025-2035)

  • recombinant human proteins
  • monoclonal antibodies
  • xenotransplantation

Healthcare By Model Organisms (USD Billion, 2025-2035)

    Healthcare By End-Users (USD Billion, 2025-2035)

    • biotechnological industry
    • research organizations
    • academic institutes
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    Customer Stories
    Case Study Cover Image
    Case Study
    Aerospace & Defense
    Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization ✓ ✓ ✓
    Direct Access to Analyst ✓ ✓ ✓
    Deliverable Format ✓ ✓ ✓
    Platform Access ✗ ✗ ✓
    Discount on Next Purchase 10% 15% 15%
    Printable Versions ✗ ✗ ✓